TY - JOUR
T1 - Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone
AU - Carella, Angelo M.
AU - Lerma, Enrica
AU - Corsetti, Maria T.
AU - Dejana, Anna
AU - Celesti, Lidia
AU - Casarino, Lucia
AU - De Stefano, Francesco
AU - Frassoni, Francesco
PY - 1998
Y1 - 1998
N2 - An immunosuppressive but not myeloablative regimen followed by HLA- matched donor mobilized haemopoietic stem cell transplantation was employed in two high-risk patients. The first patient had refractory anaemia with excess blasts (RAEB) and cytogenetic evidence of translocation 1:3(p36;q21). The second patient had Philadelphia-negative but p 190 BCR-ABL chimaeric gene positive chronic myelogenous leukaemia in accelerated phase (APCML). The conditioning regimen consisted of fludarabine (30mg/m2/d, days 1-3) with cyclophosphamide (300 mg/m2/d, days 1-3). Cyclosporine and methotrexate were employed for acute graft-versus-host disease (aGVHD) prophylaxis. In both cases the engraftment of donor cells was demonstrated by cytogenetics and short tandem repeat polymorphisms via PCR. Both patients are alive with normal cytogenetic (RAEB) and molecular (AP-CML) remissions, 100 and 150 d after allografting, respectively. In particular, in the AP-CML patient, the BCR-ABL became undetectable and the BCR-ABL/ABL ratio was
AB - An immunosuppressive but not myeloablative regimen followed by HLA- matched donor mobilized haemopoietic stem cell transplantation was employed in two high-risk patients. The first patient had refractory anaemia with excess blasts (RAEB) and cytogenetic evidence of translocation 1:3(p36;q21). The second patient had Philadelphia-negative but p 190 BCR-ABL chimaeric gene positive chronic myelogenous leukaemia in accelerated phase (APCML). The conditioning regimen consisted of fludarabine (30mg/m2/d, days 1-3) with cyclophosphamide (300 mg/m2/d, days 1-3). Cyclosporine and methotrexate were employed for acute graft-versus-host disease (aGVHD) prophylaxis. In both cases the engraftment of donor cells was demonstrated by cytogenetics and short tandem repeat polymorphisms via PCR. Both patients are alive with normal cytogenetic (RAEB) and molecular (AP-CML) remissions, 100 and 150 d after allografting, respectively. In particular, in the AP-CML patient, the BCR-ABL became undetectable and the BCR-ABL/ABL ratio was
KW - Allografting
KW - Cytogenetic remission
KW - Immunosuppressive therapy
KW - Molecular remission
UR - http://www.scopus.com/inward/record.url?scp=0031723944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031723944&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.1998.01057.x
DO - 10.1046/j.1365-2141.1998.01057.x
M3 - Article
C2 - 9827937
AN - SCOPUS:0031723944
VL - 103
SP - 565
EP - 567
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -